



YungShin Global Holding Corporation

Investor Conference

**Provide the best products
to improve human health**

Dec. 18, 2025





Disclaimers

This presentation is based on the information obtained from various sources which the Company believes to be reliable. But at some point in the future, there are a variety of factors which could cause actual results to differ materially from those statements. Therefore, please refer to the information on MOPS website as the main basis if any adjustment has been made. (<http://mops.twse.com.tw/mops/web/index>)



Table of Contents




- **YungShin Group Overview**
- **Operational Results for Q1-Q3 of year 2025**
- **Business Strategy**





Introduction of YungShin Group

A pharmaceutical Group have been established over 60 years, looking forward being a-century enterprise.





Listing History

Three subsidiaries list in TW, CN and MY.

➤ 1993- Listing of Yungshin Pharmaceutical, Taiwan



臺灣證券交易所

➤ 2000-Listing of Yung Zip Chemical, Taiwan



證券櫃檯買賣中心
Taipei Exchange

➤ 2004-Listing of Y.S.P. Southeast Asia Holding, Malaysia



➤ 2011-Listing of YungShin Global Holding, Taiwan



臺灣證券交易所

➤ 2025-Listing of Venostrum, Taiwan



臺灣證券交易所




www.yungshingroup.com



R&D and Production Planning Worldwide

Night manufacturing and operating bases cross US, CN, JP and South Asia.





YungShin Group Main Production Bases(1/2)

Subsidiaries in TW and US have been certified by USFDA.

Production bases of YSG have covered 5 continents and products sold over 35 countries.



1990


Yung Zip
(Taiwan)

1998

Carlsbad
(USA)

2004

YungShin
(Taiwan)





YungShin Group Main Production Bases(2/2)

MY, VN and IN sites have exported to Southeast Asia, middle East, North Africa and Oceania.

❖ MY
(Malaysia)



❖ VN
(Vietnam)



❖ IN
(Indonesia)



❖ active
(Malaysia)



❖ NPRA
MALAYSIA
NATIONAL
PHARMACEUTICAL
REGULATORY
AGENCY



Health
Canada

Santé
Canada



Australian Government
Department of Health
Therapeutic Goods Administration

❖ FDA
衛生福利部
食品藥物管理署
Taiwan Food and Drug Administration

❖ HSA
Health Sciences Authority

❖ PFB
香港藥劑業及毒藥管理局
PHARMACY AND POISONS BOARD OF HONG KONG

❖ BADAN POM RI
BADAN POM RI

❖ HALAL FOOD
HALAL
CERTIFIED

❖ TGA
Health Safety
Regulation

❖ MEDSAFE
New Zealand Medicines and
Medical Devices Safety Authority


❖ YUNGSHIN
YUNGSHIN GROUP



YSH Stable Business

Stable payout dividend in every economy cycle

NT/Share





Operational Results for the year of 2025Q1-Q3

Provide the best products
to improve human health





YSH Consolidated Statements of Income

Operating revenue increased by 5.79% and

Income from operations increased by 2.68% from Jan to Sep for
the year 2025 and 2024.

(Expressed in millions of NTD)

	2025 Q1-Q3	2024 Q1-Q3	Growth rate
Operating revenue	6,216	5,876	5.79
Operating costs	(3,513)	(3,282)	7.04
Gross profit	2,703	2,594	4.20
Operating expenses	(1,707)	(1,624)	5.11
Income from operations	996	970	2.68
Non-operating income & Expenses	(69)	278	(124.82)
Profit before income tax	927	1,248	(25.72)
Profit for the period	662	910	(27.25)
Earnings per share	2.31	3.08	(25.00)



YSH Consolidated balance sheet (1/2)

Comparing total assets decreased by 11.04% in 2025 and 2024.

	2025Q3	%	2024Q3	%
Cash and cash equivalents	1,271	11	1,674	13
Inventories	2,722	23	3,130	23
Accounts receivable	1,536	12	1,650	12
Other current assets	1056	9	624	5
Property, plant and equipment	3,695	31	4,593	34
Other non-current assets	1,692	14	1,787	13
Total assets	11,972	100	13,458	100



YSH Consolidated balance sheet (2/2)

Comparing total shareholder's equity decreased by 9.20% in 2025 and 2024.

(Expressed in millions of NTD)

	2025Q3	%	2024Q3	%
Short-term borrowings	296	3	871	7
Other current liabilities	1,505	12	1,754	13
Long-term borrowings	846	7	413	3
Non-current liabilities	748	6	975	7
Total shareholder's equity	8,577	72	9,445	70
Total liabilities and equity	11,972	100	13,458	100



YSH Consolidated Operating Revenue by area

Comparing consolidated revenue increased by 5.79% from Jan to Sep for the year of 2025 and 2024.

(Expressed in thousands of local currency)

Currency	2025	2024	Growth		
			Q1-Q3	Q1-Q3	rate
Taiwan TWD	4,922,549	4,565,523			7.82
USA USD	13,783	18,518			-25.57
China RMB	22,283	11,373			95.93
Japan JPY	3,635,579	3,141,146			15.74

1. The list the revenues of companies that YSH holding only more than 50% shares.
2. Operating revenue by area is based on financial report, and the growth rate is calculated in local currency.





Business Strategy


Provide the best products
to improve human health





Operating Strategy of YSH

Eight aspects to accomplish steady investment and pragmatic operation for creating the best interests of shareholders.





Business Strategy of YSH

Internal investment management and external M&A for strengthening group efficiency

The strategy will balance short, medium and long term group development and shareholders' equity



Internal investment management

•Production

Cross company platform communication and production experience optimization

•Marketing

Search, supply, marketing promotion transnationally

•Personnel(ESG)

Integrate experiences communication of joint factory inspection for national laws and regulations

•R&D

Project coordination, R&D technology transfer reducing investment

•Finance

Supervising by YSH, apply endorsement and guarantee to reduce financial burden and increase investment efficiency



External M&A

•New business

1. Obtaining factories, products and technologies and enter into the market of feed additives by merger and acquisition of Pfizer Inc.(Hsinchu plant)
2. Multi-angle consideration relating to health industry

•New market

1. Entering into OEM business by merger and acquisition of Alpha-Active and Taiwan Wa- Chein Ind. Co., Ltd.
2. New market evaluation such as in Europe...etc.

•New product/technology

1. Obtain manufacturing technology from GlyTech Inc.
2. Evaluating biological medicine, cell therapy and other fields.



CarlsbadTech (YungShin US)

Total solution from production to marketing as window for Asia company to enter US market.



Production



Labatory



History:

Company started in 1990 and facility operated in 1998.

Location:

Located 30 miles north of San Diego, 130 miles south of LAX, 90 miles from Port of Los Angeles.

Space:

cGMP compliance solid dosage form manufacturing facility (Approx. 21,000 sq.ft.).

Production Capability:

About 800mio to 1,000mio tabs capacity per year.

Customer:

Cover US 96% customers in sales channel with 50 states selling permit.


OWN BRAND、CMO、
CDMO、PACKING、RA
US market total solution





Create New Value for Share Holder Enter Capital Market

Be approval of listing in Q2 2025



TW only high potency and general inj. Manufacture

一般針劑生產線

產品 Lincosamides, Triamcinolone acetone, Toluenamic acid...

產能 2,100,000瓶/年

■ 2019 設立 ■ Isolator 無菌檢驗實驗室

■ 液體充填機 ■ 氮氣充氮隧道



液體充填機



Isolator無菌檢驗實驗室



氮氣充氮隧道


高致敏針劑生產線

產品 Amoxicillin, Cephalosporins...

產能 1,125,000瓶/年

■ 2019 設立 ■ 高效能密封式封蓋系統

■ 隧道式烘箱 ■ 精準電子秤重系統



隧道式烘箱(去熱原)



高效能密封式封蓋系統



精準電子秤重系統





Maximize Value Chain Based on Product

Strengthen the competitiveness of the group through vertical integration and horizontal expansion



Maximize Value Chain

Vertical integration : Maximize Production Value Chain

- Vertical integration of main products through manufacturing and marketing of intermediate, API and FDF.
- Master raw material intermediate suppliers through investment and contract manufacture.
- Local production reduce the risk of trade barriers.
- Sharing R&D resource from in Taiwan and Malaysia lab.
- Continually strengthen product line competitiveness (integrate value chain and expand production batch size)

Horizontal expansion : Maximize Sales Value Chain

- Future product lines drive from market orientation
- Deep development of digestive tract, pain, hypersensitivity and anticancer fields.
- Increasing investment benefit through Integration product lines in various countries, mutual distribution, technology transfer, and development together.
- Expansion of four major business: API, FDF, OTC and animal drugs



YungShin group CDMO


Business cover from API, Originator, Brand, Food supplement and Vet Drug





Diversified Business Map

Expansion and exposure new business based on core health care relative business





Core Value of YungShin Group

Provide the best products to improve human health from Taiwan



Spirit of YungShin Group :

We produce medicine that we would give it to our own families.

We establish Nursing Home that our elders would love to go to.

Social welfare covered by cooperate social responsibility



Q & A

**Provide the best products
to improve human health**
